Medicinal Products

DEPO-MEDROL 40 mg / 1 ml

Generic drug of the therapeutic class: Anti-inflammatories
active ingredients: Methylprednisolone
laboratory: Pfizer Holding France

Injectable suspension
Box of 1 pre-filled syringe of 1 ml
All forms

Indication

SYSTEMIC USE :
Seasonal allergic rhinitis after failure of other therapies (general antihistamine, intranasal corticosteroid, or short-course oral corticosteroid).
LOCAL USE :
These are those of local corticosteroid therapy, when the condition justifies a high local concentration. Any local injection prescription must be aware of the danger of infection, particularly the risk of promoting bacterial growth.
This product is indicated in the conditions:
- dermatological : keloid scars.
- ENT : intra-sinus irrigation in subacute or chronic sinusitis justifying drainage.
- rheumatologic :
. Intra-articular injections: inflammatory arthritis, osteoarthritis,
. Periarticular injections: tendinitis, bursitis,
. Soft tissue injections: talalgia, carpal tunnel syndrome, Dupuytren's disease.

Dosage DEPO-MEDROL 40 mg / 1 ml Suspension for injection Box of 1 pre-filled syringe of 1 ml

- This specialty is not suitable for inhaled administration by nebulizer.
- Anti-inflammatory equivalence (equipotence) for 5 mg prednisone: 4 mg methylprednisolone.
SYSTEMIC USE :
INTRAMUSCULAR PATH.
- Seasonal allergic rhinitis after failure of other therapies (general antihistamine, intranasal corticosteroid or oral corticosteroid in short course). 1 injection during the allergic period.
- Injections are limited to 1 per year.
LOCAL USE :
- 1/10 to 2 ml per injection depending on the place of injection and the condition to be treated.
- The injection should not be too superficial because of the risk of subcutaneous atrophy.
The injection will be repeated only in case of reappearance or persistence of symptoms.

Against indications

CONTRAINDICATED:
SYSTEMIC USE :
This drug is generally contraindicated in the following situations (there is, however, no absolute contraindication for life-threatening corticosteroid therapy):
- Hyper-sensitivity to one of the compounds,
- any infectious condition excluding specified indications (see indications),
- certain viruses in evolution (in particular hepatitis, herpes, varicella, herpes zoster),
psychotic states not yet controlled by a treatment,
- live vaccines,
- coagulation disorders, anticoagulant treatment in case of intramuscular injection or local use.
LOCAL USE :
This medicine is contraindicated in the following situations:
- Hyper-sensitivity to one of the compounds,
- local or general infection, or suspicion of infection,
- severe disorders of coagulation, anticoagulant treatment in progress.
NOT RECOMMENDED :
SYSTEMIC USE :
- This drug is generally not recommended in combination with non-antiarrhythmic drugs, giving torsades de pointes (see interactions: astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine).
- Breast-feeding: In the case of treatment at high doses and chronically, breastfeeding is not recommended.
LOCAL USE :
Breast-feeding: In case of high-dose treatment, breast-feeding is not recommended.

Depo-Medrol side effects

SYSTEMIC USE :
Rare cases of anaphylactic reactions have been reported in patients treated with parenteral corticosteroids (see warnings). Cardiac arrhythmias have also been described related to intravenous administration.
OTHER EFFECTS:
- Hydro-electrolytic disorders: hypokalemia, metabolic alkalosis, water-soluble retention, arterial hypertension, congestive heart failure.
- Endocrine and metabolic disorders: iatrogenic Cushing's syndrome, inertia of ACTH secretion, sometimes permanent adrenocortical atrophy, decrease in glucose tolerance, revelation of latent diabetes, stunting of growth in children, menstrual irregularities.
- Musculoskeletal disorders: Muscular atrophy preceded by muscle weakness (increased protein catabolism), osteoporosis, pathological fractures, particularly vertebral compression, aseptic osteonecrosis of the femoral heads.
Some cases of tendon ruptures have been described in an exceptional way, in particular in coprescription with fluoroquinolones.
- Digestive disorders: hiccups, peptic ulcers, ulceration of the small bowel, perforations and digestive haemorrhages, acute pancreatitis have been reported, especially in children.
- Skin disorders: acne, purpura, bruising, hypertrichosis, delayed healing.
- Neuropsychic disorders:
. frequently: euphoria, insomnia, excitement.
. rarely: manic pace; confusional or confuso-oniric states, convulsions.
. depressive state upon discontinuation of treatment.
- Eye disorders: some forms of glaucoma and cataracts.
LOCAL USE :
The systemic adverse effects of glucocorticoids have a low risk of occurrence after local administration, given the low blood levels but the risk of hypercorticism (retention of water and sodium, imbalance of diabetes and hypertension ...) increases with dose and frequency of injections.
- risk of local infection according to the injection site: arthritis, ...
- localized atrophy of muscle, subcutaneous and cutaneous tissues. Risk of tendon rupture when injected into the tendons,
- acute arthritis with microcrystals (with microcrystalline suspension) of early onset,
- local calcifications,
- local and general allergic reactions,
- flush: headaches and flushing may occur. They usually go away in a day or two.

Popular Posts

Category Medicinal Products, Next Article